ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 522

Analysis of Sequential Development of Pulmonary Lesions in Patients with Rheumatoid Arthritis

Ayae Tanaka1, Kazuhiro Kurasawa1, Yuta Takamura1, Tomoyuki Miyao1, Ryutaro Yamazaki2, Satoko Arai1, Takayoshi Owada1, Reika Maezawa1 and Masafumi Arima1, 1Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, 2Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Lung and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We previously reported that there was patterns of coexistence of pulmonary lesions and airway disease (AD) were common abnormities of patients with pulmonary involvement. However, it remains unknown through what pathways various pulmonary lesions develop.@The purpose of this study was to determine the sequential development of pulmonary lesions in RA. For this purpose, we examined the pattern of newly emerging pulmonary lesions and relationship between pre-existing and new lesions.

Methods: A retrospective cohort study. Subjects were consecutive 208 RA patients who started bDMARDs in our department and received HRCT scan before and during the therapy. Based on HR-CT, pulmonary abnormalities were classified 20 lesions such as ground-glass opacity (GGO), reticular pattern, and bronchiolitis. We recorded their existence and changes during the therapy. Cluster analysis was conducted according to new lesions by Ward method. A checkerboard analysis of pre-existing and new lesions was conducted.

Results: Subjects were 208 RA patients, M/F; 64/144, mean age; 59.2 years old, disease duration; 7.9 years. bDMARDs used for the longest period were TNF inhibitors in 79.8% of the subjects. Pulmonary abnormalities were found in 146 (70.2%) of RA patients (ILD 81,(38.9%); nodular lesions 45,(21.6%); and AD 115,(55.3%)) at the entry. During the observation period (3.26}2.61 years), new pulmonary lesions were found in 31.3% of patients and the incidence was 10.0/100-person year. New lesions were frequently occurred in patients with pre-existing pulmonary lesions. Cluster analysis of new lesions showed 7 clusters; Cluster 1:nodular lesions developed mainly patients with AD and reticular pattern, Cluster 2;curved linear opacities with/ without reticular pattern which occurs in patients without pre-existing diseases or bronchiolitis with nodules, Cluster3; bronchiectasis developed in patients with bronchiolitis, Cluster 4; consolidation developed in patients with pre-existing pulmonary diseases, particularly AD, Cluster 5; bronchiolitis occurred in patients with bronchiectasis, Cluster 6; no new pulmonary lesions and Cluster 7; GGO developed in patients with AD and fibrotic ILD. Similarly, a checkerboard analysis of pre-existing and new lesions revealed followings (Fig.1); 1) in patients without pre-existing lesions, bronchiolitis or curved linear opacities occurred, 2) patients with bronchiolitis developed bronchiectasis, 3) reticular pattern occurred in patients with AD (bronchiolitis/ bronchiectasis), and 4) patients with AD with reticular pattern developed GGO and/or consolidation.

Conclusion: Pulmonary lesions were developed in several patterns, not at random. Pre-existing pulmonary lesion induced new pulmonary lesions. Airway diseases, particularly bronchiolitis, might be an important lesion that induce ILD (and nodular lesions).


Disclosure: A. Tanaka, None; K. Kurasawa, None; Y. Takamura, None; T. Miyao, None; R. Yamazaki, None; S. Arai, None; T. Owada, None; R. Maezawa, None; M. Arima, None.

To cite this abstract in AMA style:

Tanaka A, Kurasawa K, Takamura Y, Miyao T, Yamazaki R, Arai S, Owada T, Maezawa R, Arima M. Analysis of Sequential Development of Pulmonary Lesions in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/analysis-of-sequential-development-of-pulmonary-lesions-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-sequential-development-of-pulmonary-lesions-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology